These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21411223)

  • 1. Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.
    Luwor RB; Lu Y; Li X; Liang K; Fan Z
    Cancer Lett; 2011 Jul; 306(1):85-91. PubMed ID: 21411223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
    Lu Y; Liang K; Li X; Fan Z
    Mol Cancer; 2007 Oct; 6():63. PubMed ID: 17931419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.
    Li X; Lu Y; Liang K; Pan T; Mendelsohn J; Fan Z
    Mol Cancer Ther; 2008 May; 7(5):1207-17. PubMed ID: 18483308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
    Takata M; Chikumi H; Miyake N; Adachi K; Kanamori Y; Yamasaki A; Igishi T; Burioka N; Nanba E; Shimizu E
    Cancer Biol Ther; 2012 Apr; 13(6):369-78. PubMed ID: 22313637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
    Jhawer M; Goel S; Wilson AJ; Montagna C; Ling YH; Byun DS; Nasser S; Arango D; Shin J; Klampfer L; Augenlicht LH; Perez-Soler R; Mariadason JM
    Cancer Res; 2008 Mar; 68(6):1953-61. PubMed ID: 18339877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
    Oliveras-Ferraros C; Massaguer Vall-Llovera A; Carrion Salip D; Vazquez-Martin A; Cufí S; Queralt B; Martin-Castillo B; Brunet J; de Llorens R; Menendez JA
    Invest New Drugs; 2012 Apr; 30(2):846-52. PubMed ID: 21161326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
    El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
    PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression.
    Luwor RB; Lu Y; Li X; Mendelsohn J; Fan Z
    Oncogene; 2005 Jun; 24(27):4433-41. PubMed ID: 15806152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
    Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
    Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
    Myers MV; Manning HC; Coffey RJ; Liebler DC
    Mol Cell Proteomics; 2012 Feb; 11(2):M111.015222. PubMed ID: 22147731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.
    Feng YH; Tsao CJ; Wu CL; Chang JG; Lu PJ; Yeh KT; Shieh GS; Shiau AL; Lee JC
    Cancer Sci; 2010 Sep; 101(9):2033-8. PubMed ID: 20624167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
    Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
    Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.